tenofovir has been researched along with fumarates in 50 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (10.00) | 24.3611 |
| 2020's | 45 (90.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caroleo, B; Gallelli, L; Perticone, F; Staltari, O | 1 |
| Desai, T; Johengen, D; Luecke, E; McGowan, I; Rothrock, G; Schlesinger, E; van der Straten, A | 1 |
| Donahue Carlson, R; Frisch, MB; Haaland, RE; Kraft, CS; Martin, A; Mehta, CC; Ofotokun, I; Patel, AS; Pau, CP; Read, TD; Sheth, AN | 1 |
| Choi, MJ; Kim, YK; Lee, S; Oh, TY; Yu, KS | 1 |
| Bogner, JR; Gomez, M; Härter, G; Roider, J; Seybold, U | 1 |
| Imai, Y; Kouyama, JI; Mochida, S; Motoya, D; Naiki, K; Nakao, M; Nakayama, N; Sugawara, K; Tomiya, T; Tsuji, S; Uchida, Y; Uemura, H | 1 |
| Cain, CM; Dobek, G; Grasperge, B; Hope, T; Karunakaran, D; Kiser, PF; Marzinke, M; Pearson, E; Peet, MM; Qiu, J; Simpson, SM; Su, JT; Sung, S; Tfaily, EB; Veazey, R; Watrous, D; Widanapathirana, L | 1 |
| Berruti, M; Briano, F; Di Biagio, A; Taramasso, L | 1 |
| Panagopoulos, P; Papachristou, S; Papanas, N; Papazoglou, D; Petrakis, V; Terzi, I; Trypsianis, G | 1 |
| Gwenden, KN; Marzinke, MA; Parsons, TL | 1 |
| Kandala, B; Vaddady, P; Yee, KL | 1 |
| Burger, DM; Mollema, FP; Roelofsen, EE; Wildenbeest, S | 1 |
| Cao, L; Huang, Y; Pan, CQ | 1 |
| Elmofti, Y; Gish, RG | 1 |
| Bai, HZ; Hu, X; Liu, L; Tang, G; Wang, JW; Yu, KX; Zhang, WH; Zhou, J | 1 |
| Hanna, GJ; Hwang, C; Kumar, S; Lin, G; Martin, E; Molina, JM; Orkin, C; Sax, PE; Squires, KE; Sussmann, O; Teppler, H | 1 |
| Mesplède, T | 1 |
| Hatakeyama, S; Kanda, N; Mieno, M; Okamoto, K; Okumura, H; Sakashita, K; Sasahara, T | 1 |
| Brahmania, M; Coffin, CS; Conway, B; Cooper, C; Doucette, K; Farag, MS; Fung, S; Hansen, BE; Haylock-Jacobs, S; Janssen, HLA; Ramji, A; Sebastiani, G; Tam, E; Tsoi, K; Wong, A; Wong, P | 1 |
| Behrens, GMN; Sandmann, L; Stoll, M | 1 |
| Bernasconi, E; Calmy, A; Cavassini, M; Kovari, H; Ledergerber, B; Rauch, A; Schmid, P; Surial, B; Tarr, PE; Wandeler, G | 1 |
| Ikeda, M; Moriya, K; Okamoto, K; Okugawa, S; Wakabayashi, Y; Yanagimoto, S | 1 |
| Duan, M; Gu, Y; Li, B; Liu, D; Liu, Q; Liu, X; Liu, Z; Ma, Q; Wang, Y; Wei, Y | 1 |
| Lai, J; Li, X; Peng, L; Wang, L; Wu, L; Xie, C; Zhang, Y; Zhu, X | 1 |
| Lyu, J; Pan, L; Teng, J; Wu, H; Zhang, F; Zhang, M; Zhu, C | 1 |
| Abe, K; Goto, T; Imamura, J; Ito, T; Kamio, S; Kondo, A; Obara, T; Sato, H; Takahashi, N | 1 |
| Hideta, K; Higasa, S; Hikasa, S; Kimura, T; Sawada, A; Shimabukuro, S; Tanaka, K; Tokugawa, T; Yanai, M | 1 |
| Ito, T; Kumada, T; Tanaka, J; Toyoda, H; Yasuda, S | 1 |
| Imai, Y; Kouyama, JI; Mochida, S; Naiki, K; Nakao, M; Nakayama, N; Sugawara, K; Tomiya, T; Tsuji, S; Uchida, Y; Uemura, H; Yamada, S | 1 |
| Kamiya, K; Kishimoto, M; Komine, M; Kuwahara, A; Morimoto, N; Ohtsuki, M; Sugai, J | 1 |
| Carrozzo, G; Cattaneo, D; Gervasoni, C; Poloni, A; Riva, A | 1 |
| Cheng, AK; Lee, WA | 1 |
| Cerankowski, J; Keith, SW; Schafer, JJ; Shimada, A; Walshe, C; Zimmerman, M | 1 |
| Bonnichsen, MH; Bye, W; Post, JJ; Tschuchnigg, M | 1 |
| Papatheodoridis, GV | 1 |
| Chen, CH; Tseng, TN | 1 |
| Liu, W; Yan, B; Yu, S | 1 |
| Ciach, T; Dąbrowska, J; Krzyżowska, M; Nowicka, M; Szymańska, E; Winnicka, K; Wojasiński, M | 1 |
| Baek, YH; Chae, HB; Cheon, GJ; Cho, HC; Cho, YK; Chon, YE; Hwang, JS; Kang, MK; Kim, JH; Kim, SU; Koh, MS; Kweon, YO; Lee, C; Lee, JH; Lee, JS; Lim, YS; Park, NH; Park, YM; Sohn, JH; Yim, HJ | 1 |
| Akahane, T; Inoue, J; Iwata, T; Kisara, N; Kobayashi, T; Masamune, A; Ninomiya, M; Onuki, M; Sano, A; Sato, K; Sato, S; Tsuruoka, M | 1 |
| Ishii, T; Onoda, T; Tanaka, H | 1 |
| Akahane, T; Inoue, J; Iwata, T; Kimura, O; Kobayashi, T; Masamune, A; Nakamura, T; Niitsuma, H; Ninomiya, M; Onuki, M; Sano, A; Sato, K; Sato, T; Sawahashi, S; Takai, S; Tsuruoka, M | 1 |
| Agrahari, V; Clark, MR; Dinh, C; Doncel, GF; García-Lerma, JG; Heneine, W; Holder, A; Makarova, N; Mendoza, M; Mitchell, J; Pan, Y; Peet, MM; Singletary, T; Smith, JM | 1 |
| Andreoni, M; Barchi, V; De Simone, G; Iannazzo, R; Iannetta, M; Massa, B; Rindi, LV; Sarmati, L | 1 |
| Agrahari, V; Clark, MR; Dinh, C; Dobard, CW; Doncel, GF; García-Lerma, JG; Gupta, P; Heneine, W; Holder, A; Jonnalagadda, S; Khalil, G; McCormick, TJ; Mitchell, J; Nishiura, K; Pan, Y; Peet, MM; Singh, ON | 1 |
| Bamford, A; Burger, DM; Bwakura-Dangarembizi, M; Chabala, C; Colbers, A; Denti, P; Doerholt, K; Gibb, DM; Griffiths, AL; Makumbi, S; McIlleron, HM; Monkiewicz, LN; Mulenga, V; Mumbiro, V; Musiime, V; Nangiya, J; Szubert, AJ; Waalewijn, H; Wasmann, RE; Wiesner, L | 1 |
| Cecka, F; Cerveny, L; Dusek, T; Halodova, V; Huliciak, M; Kocova-Vlckova, H; Lhotska, I; Staud, F; Vokral, I | 1 |
| Chiarabini, T; Devred, I; Kayembe, K; Lacombe, K; Lambert-Niclot, S; Meyohas, MC; Rougier, H; Shinga, BW; Valin, N | 1 |
| Hechter, RC; Mefford, MT; Pak, KJ; Rivera, AS | 1 |
| Liu, S; Liu, Z; Ma, X; Xin, Y; Zhao, Z | 1 |
2 review(s) available for tenofovir and fumarates
| Article | Year |
|---|---|
Evaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Female; Fumarates; HIV Infections; HIV-1; Humans; Male; Tenofovir | 2021 |
Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
Topics: Adenine; Alanine; Antiviral Agents; Bone and Bones; Creatinine; Fumarates; Hepatitis B; Hepatitis B, Chronic; Humans; Kidney; Network Meta-Analysis; Tenofovir; Treatment Outcome | 2023 |
8 trial(s) available for tenofovir and fumarates
| Article | Year |
|---|---|
A comparative pharmacokinetic and tolerability analysis of the novel orotic acid salt form of tenofovir disoproxil and the fumaric acid salt form in healthy subjects.
Topics: Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Fumarates; Healthy Volunteers; Humans; Male; Orotic Acid; Salts; Tenofovir; Young Adult | 2017 |
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Emtricitabine; Fumarates; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Tenofovir; Treatment Outcome; Triazoles | 2021 |
Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load.
Topics: Alanine; Antiviral Agents; Female; Fumarates; Hepatitis B virus; Hepatitis B, Chronic; Humans; Infant; Infectious Disease Transmission, Vertical; Pregnancy; Tenofovir; Treatment Outcome; Viral Load | 2021 |
Tenofovir alafenamide fumarate therapy in subjects with positive HBV-DNA and normal levels of alanine transaminase: a study protocol for a randomised controlled trial.
Topics: Adult; Alanine; Alanine Transaminase; DNA, Viral; Double-Blind Method; Fumarates; Humans; Randomized Controlled Trials as Topic; Tenofovir | 2021 |
Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients.
Topics: Adenine; Antiviral Agents; Creatinine; DNA, Viral; Fumarates; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Tablets; Tenofovir; Treatment Outcome; Viral Load | 2022 |
Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study.
Topics: Adenine; Alanine; Antiviral Agents; DNA, Viral; Female; Fumarates; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prospective Studies; Tenofovir; Treatment Outcome | 2022 |
Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques.
Topics: Adenine; Animals; Anti-HIV Agents; Female; Fumarates; HIV Infections; Macaca; Pre-Exposure Prophylaxis; Tenofovir | 2022 |
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Child; Darunavir; Emtricitabine; Fumarates; HIV Infections; Humans; Lopinavir; Protease Inhibitors; Ritonavir; Tenofovir | 2023 |
40 other study(ies) available for tenofovir and fumarates
| Article | Year |
|---|---|
Reactivation of chronic hepatitis B during treatment with tenofovir disoproxil fumarate: drug interactions or low adherence?
Topics: Alanine Transaminase; Antiviral Agents; Central Nervous System Agents; Depression; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Fumarates; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Medication Adherence; Middle Aged; Tenofovir; Transaminases; Viral Load; Virus Activation | 2015 |
A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis.
Topics: Adenine; Alanine; Anti-HIV Agents; Biodegradable Plastics; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Delivery Systems; Drug Liberation; Fumarates; HIV-1; Particle Size; Polyesters; Polymers; Pre-Exposure Prophylaxis; Solubility; Tenofovir | 2016 |
The Female Genital Tract Microbiome Is Associated With Vaginal Antiretroviral Drug Concentrations in Human Immunodeficiency Virus-Infected Women on Antiretroviral Therapy.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Cohort Studies; Deoxycytidine; Emtricitabine; Female; Fumarates; Genitalia, Female; HIV Infections; Humans; Microbiota; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Young Adult | 2017 |
A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cohort Studies; Female; Fumarates; Germany; HIV Seropositivity; Hospitals, University; Humans; Male; Middle Aged; Retrospective Studies; Tenofovir; Weight Gain; Weight Loss | 2019 |
Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
Topics: Adenine; Aged; Alanine; Antibodies, Viral; Antiviral Agents; Female; Fumarates; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Japan; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Surveys and Questionnaires; Tenofovir; Transaminases; Treatment Outcome | 2020 |
A Subcutaneous Implant of Tenofovir Alafenamide Fumarate Causes Local Inflammation and Tissue Necrosis in Rabbits and Macaques.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Delayed-Action Preparations; Drug Implants; Female; Fumarates; HIV Infections; Humans; Inflammation; Macaca mulatta; Male; Necrosis; Polyurethanes; Rabbits; Subcutaneous Tissue; Tenofovir | 2020 |
The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Female; Fumarates; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Rilpivirine; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Weight Gain | 2020 |
Tenofovir Alafenamide Fumarate Therapy for HIV Treatment: Cardiometabolic and Renal Safety.
Topics: Alanine; Anti-HIV Agents; Cardiovascular Diseases; Female; Fumarates; HIV Infections; Humans; Kidney; Male; Retrospective Studies; Tenofovir | 2020 |
Interspecies Differences in Tenofovir Alafenamide Fumarate Stability in Plasma.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Dogs; Fumarates; HIV Infections; Rabbits; Sheep; Tenofovir | 2020 |
Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1.
Topics: Anti-HIV Agents; Emtricitabine; Fumarates; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Tenofovir; Triazoles | 2020 |
Pharmacokinetics of tenofovir disoproxyl fumarate/emtricitabine in a client on pre-exposure prophylaxis after a total gastrectomy.
Topics: Adolescent; Adult; Anti-HIV Agents; Emtricitabine; Fumarates; Gastrectomy; HIV Infections; Humans; Middle Aged; Pre-Exposure Prophylaxis; Tenofovir; Young Adult | 2020 |
Editorial: tenofovir alafenamide fumarate-a new bullet to prevent mother-to-child transmission of hepatitis B virus. Authors' reply.
Topics: Adenine; Alanine; Child; Cohort Studies; Female; Fumarates; Hepatitis B virus; Humans; Infectious Disease Transmission, Vertical; Safety; Tenofovir | 2020 |
Editorial: tenofovir alafenamide fumarate-a new silver bullet to prevent mother-to-child transmission of hepatitis B virus.
Topics: Adenine; Alanine; Child; Cohort Studies; Female; Fumarates; Hepatitis B virus; Humans; Infectious Disease Transmission, Vertical; Safety; Tenofovir | 2020 |
On the Single-Crystal Structure of Tenofovir Alafenamide Mono-Fumarate: A Metastable Phase Featuring a Mixture of Co-Crystal and Salt.
Topics: Anti-HIV Agents; Chemistry Techniques, Synthetic; Crystallography, X-Ray; Fumarates; Models, Molecular; Molecular Conformation; Molecular Structure; Salts; Spectrum Analysis; Tenofovir | 2020 |
Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-1-infected patients: a real-world study in Japan.
Topics: Adult; Alanine; Anti-HIV Agents; Fumarates; HIV Infections; HIV-1; Humans; Japan; Prospective Studies; Tenofovir | 2021 |
Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study.
Topics: Alanine; Canada; Fumarates; Hepatitis B, Chronic; Humans; Kidney; Tenofovir | 2021 |
Hypophosphatemia in people with HIV: no benefit when switching from tenofovir disoproxil fumarate to tenfovir alafenamide.
Topics: Anti-HIV Agents; Fumarates; HIV Infections; Humans; Hypophosphatemia; Retrospective Studies; Tenofovir | 2021 |
Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study.
Topics: Alanine; Alanine Transaminase; Anti-HIV Agents; Cohort Studies; Fumarates; Hepatitis, Viral, Human; HIV Infections; Humans; Male; Middle Aged; Switzerland; Tenofovir | 2021 |
Changing trends in lipid profile and biomarkers of renal function and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study.
Topics: Alanine; Anti-HIV Agents; Biomarkers; Fumarates; HIV Infections; Humans; Kidney; Lipids; Prospective Studies; Tenofovir | 2021 |
Analytical Lifecycle Management (ALM) and Analytical Quality by Design (AQbD) for analytical procedure development of related substances in tenofovir alafenamide fumarate tablets.
Topics: Adenine; Alanine; Anti-HIV Agents; Chromatography, Liquid; Fumarates; HIV Infections; Humans; Tablets; Tenofovir | 2022 |
Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate: a single-center observational study.
Topics: Alanine; Anti-HIV Agents; Fumarates; HIV Infections; HIV-1; Humans; Japan; Kidney; Tenofovir | 2021 |
Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on estimated glomerular filtration rate slope in patients with HIV: A retrospective observational study.
Topics: Alanine; Anti-HIV Agents; Fumarates; Glomerular Filtration Rate; HIV Infections; Humans; Retrospective Studies; Tenofovir | 2022 |
Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B.
Topics: Adenine; Alanine; Antiviral Agents; Fumarates; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Retrospective Studies; Tenofovir; Treatment Outcome | 2021 |
Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog.
Topics: Aged; Alanine; Antiviral Agents; Drug Substitution; Female; Follow-Up Studies; Fumarates; Genotype; Guanine; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Nucleosides; Prospective Studies; Tenofovir; Treatment Outcome | 2022 |
Case of psoriasis with hepatitis B virus infection during tumor necrosis factor inhibitor treatment successfully treated with ixekizumab and tenofovir alafenamide fumarate.
Topics: Adenine; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Fumarates; Hepatitis B; Hepatitis B virus; Humans; Psoriasis; Tenofovir; Tumor Necrosis Factor Inhibitors | 2022 |
Doravirine/tenofovir disoproxyl fumarate/lamivudine-induced alopecia: A case report.
Topics: Alopecia; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Fumarates; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Pyridones; Tenofovir; Triazoles; Viral Load | 2022 |
Tenofovir alafenamide fumarate.
Topics: Adenine; Alanine; Anti-HIV Agents; Fumarates; HIV Infections; HIV-1; Humans; Tenofovir | 2022 |
Weight changes in patients with sustained viral suppression switching tenofovir disoproxil fumarate to tenofovir alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cardiovascular Diseases; Cholesterol; Drug Substitution; Fumarates; HIV Infections; Humans; Retrospective Studies; Sustained Virologic Response; Tenofovir; Weight Gain | 2022 |
Pill related oesophagitis due to tenofovir disproxil fumarate/emtricitabine (Truvada) HIV pre-exposure prophylaxis.
Topics: Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Esophagitis; Fumarates; HIV Infections; Humans; Pre-Exposure Prophylaxis; Tenofovir | 2022 |
Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic hepatitis B patients-author's reply.
Topics: Adenine; Alanine; Bone Density; Fumarates; Hepatitis B, Chronic; Humans; Kidney; Tenofovir | 2022 |
Editorial: changes in renal function and bone mineral density after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B.
Topics: Adenine; Alanine; Bone Density; Fumarates; Hepatitis B, Chronic; Humans; Kidney; Tenofovir | 2022 |
Effect of alcohol exposure on the efficacy and safety of tenofovir alafenamide fumarate, a major medicine against human immunodeficiency virus.
Topics: Adenine; Alanine; Alcohol Drinking; Anti-HIV Agents; Carboxylic Ester Hydrolases; Chromatography, Liquid; Ethanol; Fumarates; HIV; HIV Infections; Humans; Lipids; Organophosphates; Tandem Mass Spectrometry; Tenofovir | 2022 |
Chitosan-poly(ethylene oxide) nanofibrous mat as a vaginal platform for tenofovir disoproxyl fumarate - The effect of vaginal pH on drug carrier performance.
Topics: Chitosan; Drug Carriers; Ethylene Oxide; Female; Fumarates; Humans; Hydrogen-Ion Concentration; Nanofibers; Polyethylene Glycols; Polymers; Tenofovir | 2022 |
Understanding the Actual Use of Anti-HIV Drugs in Japan from 2016 to 2019: Demonstrating Epidemiological Relevance of NDB Open Data Japan for Understanding Japanese Medical Care.
Topics: Anti-HIV Agents; Fumarates; HIV Infections; Humans; Integrases; Japan; Tablets; Tenofovir | 2022 |
Switching to Tenofovir Alafenamide Fumarate in Chronic Hepatitis B Patients Who Had Detectable HBV DNA during Treatment with Entecavir.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Fumarates; Hepatitis B, Chronic; Humans; Liver Neoplasms; Tenofovir; Treatment Outcome | 2022 |
Pharmacokinetics and efficacy of topical inserts containing tenofovir alafenamide fumarate and elvitegravir administered rectally in macaques.
Topics: Alanine; Animals; Anti-HIV Agents; Female; Fumarates; HIV Infections; Leukocytes, Mononuclear; Macaca; Tenofovir; Tissue Distribution | 2022 |
Doravirine/lamivudine/tenofovir disoproxil fumarate-induced hypertriglyceridemia in a newly diagnosed AIDS patient.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Emtricitabine; Fumarates; HIV Infections; Humans; Hypertriglyceridemia; Lamivudine; Tenofovir | 2022 |
Effect of P-glycoprotein and Cotreatment with Sofosbuvir on the Intestinal Permeation of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Fumarate.
Topics: Adenine; Alanine; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Fumarates; HIV Infections; Humans; Sofosbuvir; Tenofovir | 2023 |
Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV.
Topics: Adult; Anti-HIV Agents; Cobicistat; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Fumarates; HIV Infections; Humans; Lamivudine; Tenofovir | 2023 |
Use of Tenofovir Alafenamide Fumarate for HIV Pre-Exposure Prophylaxis and Incidence of Hypertension and Initiation of Statins.
Topics: Adenine; Adolescent; Adult; Female; Fumarates; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Incidence; Male; Pre-Exposure Prophylaxis; Retrospective Studies; Tenofovir | 2023 |